United Therapeutics ( (UTHR) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
United Therapeutics shares are under pressure as traders take profits after a strong rally driven by earlier optimism. The stock’s recent run-up had been fueled by aggressive capital return plans and upbeat drug data, leaving valuations stretched in the eyes of some investors.
Earlier, sentiment jumped when the company unveiled a $2 billion buyback program, including a $1.5 billion accelerated deal with Citibank. Confidence was further boosted by positive Phase 3 results for ralinepag, which showed a 55 percent reduction in the risk of clinical worsening in pulmonary arterial hypertension patients.
More about United Therapeutics
YTD Price Performance: 10.03%
Average Trading Volume: 440,250
Technical Sentiment Signal: Buy
Current Market Cap: $23.5B
For further insights into UTHR stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.